MedTrace Logo

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

NCT06087458 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-10-15

No results posted yet for this study

Summary

The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.

Conditions

Interventions

BIOLOGICAL

VOY-101

VOY-101

Sponsors & Collaborators

  • Perceive Biotherapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Anne Fung, MD · Perceive Biotherapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-21
Primary Completion
2027-06-30
Completion
2028-03-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06087458 on ClinicalTrials.gov